Eurofins Scientific (+3.49% at 71.79 euros)

The laboratory analysis group topped the leaderboard of the Parisian stock exchange's flagship index, marking its second consecutive session in positive territory.



AOF - LEARN MORE
Key Points

 -  World leader, founded in 1987, in bio-analysis spanning biopharmaceutical services, food products, environmental testing, clinical diagnostics, consumer testing, and industrial testing technology solutions;

- Growing international presence, with €6.7 billion in revenue generated, 51% from Europe and 38% from North America;

- Business model built on 4 pillars: market coverage via "spoke" laboratories for basic testing and "hub" competence centers, external growth, ownership of real estate assets, and penetration of the Asian market;

- Capital controlled by the founding Martin family (32.7% of capital and over 50% of voting rights), with Gilles Martin serving as Chairman and CEO of the 8-member board.

Challenges



- Business model agility:

      - investments focused on 3 high-growth sectors: food (notably PFAS), medical biology (genetic testing), and environment, with cautious diversification such as battery material laboratories,

      - organization as networks of SMEs granting autonomy to operational entities–950 laboratories, each country among the 60 with a dedicated service center - payroll, procurement…,

      - securing the network by increasing group ownership of major laboratories to 34.5%, representing an annual investment of about €200 million until 2027,
      - focus on acquisitions : 15 by end-September expected to generate an additional €250 million in revenue for the year,


      
- expansion of real estate ownership for laboratory sites (35% as of end-June), further increased in the short term by acquiring minority stakes in certain sites, adding 33% more owned space, resulting in rent savings,
                  - innovation supported by longstanding partnerships with research institutions:
                    - coordination of proprietary data management systems
                    - 200,000 analysis methods
                    - laboratories and solution platforms owned in-house (LIMS system), BioPrint databases, and the launch of DiscoveryAI (reducing time-to-market for drugs by 20%),
                    - support for over 320 start-ups, contributing to more than 11% of revenue growth since 2000, notably in in vitro diagnostics, genomics, and biomarkers for liver transplantation; 


 - Environmental strategy targeting carbon neutrality by 2025 through:

      - widespread measurement of emissions generated by each site,

      - use of carbon credits and participation in the Livelihood Carbon Fund,

      - circular management and investment in solar farms;

- Strong scientific and strategic legitimacy - resilient activity, high barriers to entry, longstanding partnerships with research institutions, more than 200,000 analysis methods;

- Controlled balance sheet: debt leverage of 1.9 and free cash flow of €801 million.

Risks

- Business marked by strong seasonality (sluggish start to the year), sensitivity to weather conditions, and currency effects, with the impact on revenue increasing since the start of the year; 
- Awaiting a rebound in biopharma sales, which have shown disappointing growth; 

- After a 5.3% rise in revenue over the first nine months of the year, 2025 targets:
                  - unchanged at constant exchange rates: organic revenue growth around 5% and improvement in operating margin; 
                  - lowered at current exchange rates: organic revenue growth around 5% and operating margin 20 basis points lower than in 2024, at 22.3%;
- 2027 outlook unchanged: revenue close to €10 billion, operating margin above 24%, free cash flow close to €1.5 billion, and leverage around 1.5; 
- 2024 dividend up to €0.60.